Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

4 Apr 2011 07:00

RNS Number : 1957E
ViaLogy PLC
04 April 2011
 



VIALOGY PLC ("VIALOGY" or "THE COMPANY")

 

TRADING UPDATE

QUARTERLY BUSINESS HIGHLIGHTS

 

London, April 4, 2011, ViaLogy PLC (LSE: VIY). ViaLogy reports the following business highlights for the quarter ending March 31.

ViaLogy has made significant progress in its strategy of winning major global oil and gas industry clients, applying QuantumRD in major onshore and offshore exploration and development projects, and positioning QuantumRD as an accepted risk reduction technology in the industry's mainstream. Having completed technical discussions and successfully concluded technology demonstration projects, detailed contract proposals have been requested and submitted both to a Fortune Global 500 E&P firm and a major National OilCompany. ViaLogy's work should complement and enhance industry tools, and the Board's intention is that it should also establish both price and revenue levels for its QuantumRD technology. Successful application of the technology could spell capital expenditure savings as well as more accurate drilling locations for the two clients. Contract timing will depend in part on government approval for work in national lease properties and specific contract terms and conditions.

Under a previously announced contract ViaLogy has analysis underway on seismic data provided for a prospect owned by a supermajor company.

ViaLogy has also launched a development project to extend the use of Quantum Resonance Interferometry (QRI), its fundamental patented IP, to the shale gas microseismic market. This rapidly developing market segment utilises seismic data to monitor subsurface activity during the fracturing process, a key step in the production of natural gas. Vast natural gas deposits in the US and elsewhere will depend upon microseismic analysis for extraction. ViaLogy believes its weak signal detection technology, and its ability to detect subtle fractures, can both reduce costs and facilitate production. Natural gas is projected to account for 24% of the global energy supply by 2020 and shale gas is expected to account for over 64% of the natural gas in the US by 2020.  ViaLogy is pursuing this work in conjunction with an international oilfield services company.

 

ViaLogy recently received notice that its QRI technology patent has been officially allowed in China, an important step in protecting ViaLogy's future market position in that country. Patents have already been issued in the US and Europe.

In an update to the January announcement reporting a successful well based on QuantumRD analysis, initial production has been established at over 100 barrels per day. Hydrocarbon zone depths and porosities conform to ViaLogy's projections.

CEO Robert Dean commented, "ViaLogy continues to make impressive progress as measured against our ambitious business objectives. For over a year most of our limited resources have been focused on further development of the technology, on demonstrating its use as a risk-reduction tool in the context of an accepted industry workflow suite, and its application and efficacy in tough exploration prospects by clients whose recognition will be critical to business growth. Pre-contract work for our prospective clients has contributed to a real spirit of partnership. Also, the importance of natural gas as a current and future energy source has convinced us that we have to devote effort to enter this adjacent market for our technology." 

For further information contact:

 

ViaLogy PLC

 

Terry Bond, Chairman - UK & Europe +44 (0) 1235 834 734

 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

 

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 207 107 8000

 

Katie Ratner / Jeremy Stephenson, Corporate Broking +44 (0) 207 107 8000

 

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery.

 

ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKXLFBFZFLBBV
Date   Source Headline
7th Feb 20177:00 amRNSSouthern Europe Business Update
10th Jan 20173:33 pmRNSResult of General Meeting
10th Jan 20177:15 amRNSHardman Research: Yourgene improves growth
21st Dec 20164:00 pmRNSPosting of Circular
21st Dec 20167:00 amRNSHalf year results
21st Dec 20167:00 amRNSConditional Acquisition of Yourgene Bioscience
21st Nov 20167:00 amRNSPremaitha establishes first service lab in Asia
31st Oct 20167:00 amRNSPremaitha welcomes UK Govt. decision on NIPT
27th Oct 20164:10 pmRNSResult of AGM
27th Oct 20167:00 amRNSAGM Statement
21st Oct 20167:00 amRNSGrant of Options
3rd Oct 20167:15 amRNSHardman Research: Excellent first year for IONA®
30th Sep 20163:38 pmRNSNotice of AGM
30th Sep 20167:00 amRNSFinal Results
23rd Sep 201610:42 amRNSHolding(s) in Company
23rd Sep 20168:50 amRNSNotice of results & appointment of broker
23rd Sep 20168:50 amRNSInvestment agreement extension with Thermo Fisher
8th Sep 20169:08 amRNSDirectorate Change
6th Jul 20167:00 amRNSDirectorate Change
4th Jul 20167:00 amRNSProgress on anti-trust objections to litigation
22nd Jun 20167:00 amRNSAdoption of Financial Reporting Standard (FRS) 101
22nd Apr 201610:45 amRNSUpdate on competitor patent litigation
20th Apr 201611:14 amRNSHardman Research: IONA sales & litigation update
20th Apr 20167:00 amRNSPatent Litigation Rescheduled
18th Apr 20161:13 pmRNSHardman & Co Issues Research Report
18th Apr 20161:03 pmRNSHardman & Co Issues Research Report
14th Apr 20167:00 amRNSHolding(s) in Company
13th Apr 20169:52 amRNSHolding(s) in Company
13th Apr 20167:00 amRNSHoldings in Company, Director's Shareholding
11th Apr 20167:00 amRNSTrading Update
29th Mar 20167:00 amRNSPremaitha announces tenth customer laboratory
21st Mar 20167:00 amRNSDistribution Agreements in the Middle East
9th Mar 20165:21 pmRNSHolding in Company, Directors' Dealing Replacement
9th Mar 20163:33 pmRNSHolding in Company, Directors' Dealings
9th Mar 20167:00 amRNSDistribution Agreement with GeNext - Russia
7th Mar 20167:00 amRNSAppointment of Joint Broker
3rd Feb 20167:00 amRNSPremaitha partners with Visional Medical in India
2nd Feb 20167:00 amRNSPremaitha partners with Leeds Hospitals NHS Trust
28th Jan 20167:00 amRNSHardman & Co Research Report: IONA®-Up and running
27th Jan 20167:00 amRNSTwo new customers signed for clinical lab service
26th Jan 20162:29 pmRNSUpdate on UK Litigation Timing
15th Jan 20167:00 amRNSPremaitha welcomes NSC recommendation on NIPT
8th Jan 201612:40 pmRNSUpdate on competitor patent litigation
18th Dec 20157:00 amRNSDirector/PDMR Shareholding
16th Dec 20155:53 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSHardman Issues Research Report
14th Dec 20157:00 amRNSInvestment Agreement with Thermo Fisher Scientific
14th Dec 20157:00 amRNSHalf Yearly Report
11th Dec 20157:00 amRNSNotice of Half Year Results
2nd Dec 20157:00 amRNSFirst IONA® testing service in France at LaboSud

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.